SEC Form 4 · accession 0001209191-15-075193

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 13, 2015

Accepted (ET)

Oct 13, 2015 · 1:22 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001557746

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Oct 13, 2015	C	46,188	—	A	394,014	I	By Trust
Common Stock^F4	holding	—	—		—	521,739	I	By NeXeption, LLC

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F3,F2	—	Oct 13, 2015	C	110,000	D	—	—	Common Stock	31,884	I
Series B Preferred Stock^F3,F2	—	Oct 13, 2015	C	31,913	D	—	—	Common Stock	9,250	I
Series C Preferred Stock^F3,F2	—	Oct 13, 2015	C	17,437	D	—	—	Common Stock	5,054	I

F1The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
F2Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
F3These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which Mr. Tullman's spouse serves as the trustee.
F4These shares are held by NeXeption, LLC, of which Mr. Tullman is the Manager.